IKT - Inhibikase Therapeutics reports Q1 results May, 17 2021 04:48 PM Inhibikase Therapeutics Inc. Inhibikase Therapeutics (IKT): Q1 GAAP EPS of -$0.26.Cash and cash equivalents were $9.6 million as of March 31, 2021.Press release. For further details see: Inhibikase Therapeutics reports Q1 results